GLP-1 RAs are progressively replacing these conventional therapies due to their favorable safety profile, particularly the markedly lower risk of hypoglycemia and the additional benefit of promoting weight loss, rather than weight gain—an adverse effect commonly associated with older antidiabetic drugs [1]. The gene discussed is GLP1R; the disease is Hypoglycemia.